AKT2 and non-small cell lung carcinoma: These effects were selective for EGFR M+ NSCLC cells (compared with EGFR WT), indicating that AKT2 and possibly AKT1, play an important role in conferring resistance of EGFR M+ cells to gefitinib induced apoptosis and growth inhibition.